摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

去氧哈林通碱 | 36804-95-2

中文名称
去氧哈林通碱
中文别名
脱氧三尖杉酯碱
英文名称
deoxyharringtonine
英文别名
1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-hydroxy-2-(3-methylbutyl)butanedioate
去氧哈林通碱化学式
CAS
36804-95-2
化学式
C28H37NO8
mdl
——
分子量
515.604
InChiKey
WRCBXHDQHPUVHW-QKBZBAIHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    645.8±55.0 °C(Predicted)
  • 密度:
    1.30±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    37
  • 可旋转键数:
    10
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    104
  • 氢给体数:
    1
  • 氢受体数:
    9

SDS

SDS:a7fbd11b9e1e61a7c07b4947ac6a5bc2
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

点击查看最新优质反应信息

文献信息

  • PROCESS FOR PREPARING CEPHALOTAXINE ESTERS
    申请人:Robin Jean-Pierre
    公开号:US20120022250A1
    公开(公告)日:2012-01-26
    A process for preparing cephalotaxine esters corresponding to the following general formula I which comprises the cephalotaxine backbone: C(R 1 )(R 2 )(XH)COO[CTX] wherein CTX represents the cephalotaxine backbone, being optionally substituted and/or dehydrogenated, in which formula I, X is a heteroatom, preferably an oxygen, a sulfur or a nitrogen, R 1 and R 2 , taken separately, may be alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, heterocycloalkyl or aralkyl groups, said groups being optionally interrupted by ester functions, or groups that can form one or more rings or a heterocycle together, consisting in bringing the corresponding cephalotaxine compound, or salts, isomers or tautomeric forms thereof, which is free or which is in the form of a metal alkoxide corresponding to the following general formula CTXOM, wherein CTX represents the cephalotaxine backbone, being optionally substituted and/or dehydrogenated, in which M is a hydrogen atom or a metal atom, into contact with a heterocyclic side chain precursor having both a bifunctional protected (bidentate) and activated (acylating) form of an acid bearing a hydrogenated heteroatom, in the alpha (α) position with respect to the carboxyl group, and corresponding to the following general formula: in which case W is a carbon, sulfur, silicon or bore atom, X, R 1 and R 2 have respectively the same meaning as above, it being possible for R 1 and R 2 to form a ring or a heterocycle together, and Y and Z are alkyl or heteroalkyl radicals, or monovalent heteroatoms, which may be identical or different, in an independent manner, or may fuse so as to give a divalent heteroatom, it being possible for the X—W bond to be covalent or ionic.
    一种制备对应以下一般式I的头叶松碱酯的方法,其中包括头叶松碱骨架:C(R1)(R2)(XH)COO[CTX],其中CTX代表头叶松碱骨架,可以是可选择地取代和/或脱氢的,在该式I中,X是一个杂原子,优选为氧、硫或氮,R1和R2,分别取,可以是烷基、环烷基、杂基、芳基、杂芳基、杂环烷基或芳基,这些基团可以通过酯功能团中断,或者可以形成一个或多个环或一个杂环,包括将相应的头叶松碱化合物,或其盐、异构体或互变异构体形式,该化合物是自由的或以金属烷氧基的形式存在,对应以下一般式CTXOM,其中CTX代表头叶松碱骨架,可以是可选择地取代和/或脱氢的,在该式中,M是氢原子或金属原子,与具有双功能保护(双齿)和活化(酰化)形式的酸的α位上带有氢杂原子的杂环侧链前体接触,该酸与羧基相对应,并对应以下一般式:在这种情况下,W是碳、硫、硅或硼原子,X、R1和R2分别具有与上述相同的含义,R1和R2可以共同形成一个环或一个杂环,Y和Z是烷基或杂基基,或一价杂原子,可以独立地相同或不同,或者可以融合以形成二价杂原子,X—W键可以是共价键或离子键。
  • Synthesis of AntiproliferativeCephalotaxus Esters and Their Evaluation against Several Human Hematopoietic and Solid Tumor Cell Lines: Uncovering Differential Susceptibilities to Multidrug Resistance
    作者:Joseph D. Eckelbarger、Jeremy T. Wilmot、Matthew T. Epperson、Chandar S. Thakur、David Shum、Christophe Antczak、Leonid Tarassishin、Hakim Djaballah、David Y. Gin
    DOI:10.1002/chem.200701998
    日期:2008.5.9
    isolated from the Cephalotaxus genus. Convergent syntheses of these four natural products are described, each involving novel synthetic methods and strategies. These syntheses enabled evaluation of several advanced natural and non-natural compounds against an array of human hematopoietic and solid tumor cells. Potent cytotoxicity was observed in several cell lines previously not challenged with these
    据报道,脱氧三尖杉酯碱 (2)、高三尖杉酯碱 (3)、高脱氧三尖杉酯碱 (4) 和脱水三尖杉酯碱 (5) 是从三尖杉属分离的抗白血病生物碱中最有效的成员。描述了这四种天然产物的收敛合成,每一种都涉及新的合成方法和策略。这些合成使得能够针对一系列人类造血和实体肿瘤细胞评估几种先进的天然和非天然化合物。在先前未用这些生物碱攻击的几种细胞系中观察到强细胞毒性。该生物碱家族内酯链结构的变化赋予了针对长春新碱抗性 HL-60/RV+ 的不同活性谱,为这些天然产物的分子设计以对抗多药耐药性提供了新的途径。
  • Diastereoselective Synthesis of Cephalotaxus Esters via Asymmetric Mukaiyama Aldol Reaction
    作者:Guo-Zhen Ma、Peng-Fei Li、Lu Liu、Wei-Dong Z. Li、Li Chen
    DOI:10.1021/acs.orglett.7b00743
    日期:2017.5.5
    carbon stereocenter of the side chain of cephalotaxus esters by means of highly diastereoselective Mukaiyama aldol reactions between α-keto esters (2) and a (Z)-α-chloro ketene silyl acetal. This protocol permitted synthesis of cephalotaxus esters including six natural products in good to excellent yields (up to 94%) with high diastereoselectivities (dr up to 97:3) and could be performed on a multigram
    我们报告了协议的高效立体选择性安装头孢酯侧链的手性含氧四取代叔碳立体中心通过α-酮酸酯(2)和(Z)-α-氯之间的高度非对映选择性的Mukaiyama羟醛反应乙烯酮甲硅烷基缩醛。该方案允许合成头孢菌素酯,包括具有高非对映选择性(dr高达97:3)的高至极佳产率(高达94%)的六种天然产物,并且可以以多克规模进行。
  • (﹣)-三尖杉碱的酯类衍生物的合成方法及其中间体
    申请人:中国科学院上海有机化学研究所
    公开号:CN110577506B
    公开(公告)日:2023-04-07
    本发明公开了(﹣)‑三尖杉碱的酯类衍生物的合成方法及其中间体。本发明的合成方法包括如下步骤:在溶剂中,在缩合剂的作用下,将化合物A与化合物4进行如下所示的缩合反应得到化合物I即可。本发明的合成方法利用消旋的环氧支链化合物与(﹣)‑三尖杉碱进行酯化反应,高选择性的得到接近构型单一的手性化合物,合成路线简单、温和、易于工业化。
  • [EN] COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES<br/>[FR] PRODUIT ASSOCIANT UN INHIBITEUR DE BCL-2/BCL-XL ET UN AGENT CHIMIOTHÉRAPEUTIQUE, ET UTILISATION ASSOCIÉE DANS LA PRÉVENTION ET/OU LE TRAITEMENT DE MALADIES
    申请人:ASCENTAGE PHARMA SUZHOU CO LTD
    公开号:WO2021018240A1
    公开(公告)日:2021-02-04
    Provided herein is a combination product comprising a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent, in particular a Bcl-2/Bcl-xL inhibitor of formula (I-A) and homoharringtonine or an active derivative thereof, in free or pharmaceutically acceptable salt or solvate form. Provided herein is also the use of the aforementioned combination for the preparation of a medicament for the prevention and/or treatment of cancer, in particular of hematological malignancies, and to a method for the prevention and/or treatment of cancer, in particular of hematological malignancies, using the aforementioned combination.
    本文提供的是一种组合产品,包括一种Bcl-2/Bcl-xL抑制剂和一种化疗药物,特别是一种式(I-A)的Bcl-2/Bcl-xL抑制剂和同喜树碱或其活性衍生物,以自由形式或药学上可接受的盐或溶剂形式。本文还提供了上述组合物用于制备用于预防和/或治疗癌症,特别是血液恶性肿瘤的药物的用途,并提供了一种使用上述组合物进行预防和/或治疗癌症,特别是血液恶性肿瘤的方法。
查看更多

同类化合物

高三尖杉酯碱酰胺 高三尖杉酯碱 氧桥三尖杉碱 异三尖杉酯碱 双(去甲基)-脱氧三尖杉酯碱 去甲基三尖杉酮碱 去氧哈林通碱 乙酰三尖杉碱 三尖杉酯碱 三尖杉碱 4-羟基三尖杉碱 4'-去甲基高三尖杉酯碱 (1S,3aR)-1,5,6,8,9,14bbeta-六氢-2-甲氧基-4H-环戊并[a][1,3]二氧杂环戊并[4,5-H]吡咯并[2,1-b][3]苯并氮杂卓-1alpha,9alpha-二醇 (-)-脱水三尖杉酯碱 nordeoxyharringtonine cephalotaxine 4′-demethylharringtonine homoharringtonine α-N-oxide cephalotaxine α-N-oxide cephalotaxine α-N-oxide cephalotaxine β-N-oxide (2R,3R,4S,5S)-2,3-bis(tert-butyldiphenylsilyloxy)-cephalotaxan-8-one (2S,3R,5S,7S)-3-methyl-4,17,19-trioxa-11-azahexacyclo[12.7.0.02,7.03,5.07,11.016,20]henicosa-1(21),14,16(20)-triene (2S,6S)-3-methyl-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),3,13,15(19)-tetraene (1S)-2-methoxy-(3atC4,14bt)-1,5,6,8,9,14b-hexahydro-4H-1r,9c-epioxido-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine 1-O-[(2R,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate 2,3,5,6,8,9-hexahydro-1-(pivaloyloxy)-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine Dimethyl 3-(trifluoromethylsulfonyloxy)-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),2,7,13,15(19)-pentaene-7,8-dicarboxylate Alkaloid D Epicephalotaxin Cephalotaxin a u. b (3aα,4aS*,15bβ,15cα)-(+/-)-3a,4,6,7,9,10,15b,15c-octahydro-2,2-dimethyl-5H-<1,3>dioxolo<4,5-h>-1,3-dioxolo<4,5>cyclopenta<1,2-a>pyrrolo<2,1-b><3>-benzazepine 4-Hydroxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-3-one (Ξ)-2-methyl-2-(2,2,2-trichloro-ethoxycarbonyloxy)-butyric acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-2-methoxy-1t-(2,2,2-trichloro-ethoxycarbonyloxy)-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-phenyl-(2,2,2-trichloro-ethoxycarbonyloxy)-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester oxalic acid ethyl ester (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-1t-benzyloxycarbonyloxy-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-hydroxy-phenyl-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester [(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] (2R)-2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-2,6-dihydroxy-6-methylheptanoate (+/-)-3-dehydroxy-2-demethoxy-1,2-dihydro-2,8-dioxocephalotaxine epi-deoxyharringtonine hexa-2t,4t-dienoic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester Dehydrodeoxyhomoharringtonine [(2S,4S,6S)-12-methylsulfanyl-11-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-4-yl] acetate Omacetaxine mepesuccinate hydrochloride cephalotaxinamide (1R,2S,3aS,14bR)-1,2,3,5,6,8,9,14b-Octahydro-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine-1,2-diol methylfumaric acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester 11alpha-Hydroxycephalotaxine